Posted by Michael Wonder on 21 Dec 2016
Astellas announces FDA fast track designation for ASP0892, DNA vaccine for mitigation of severe hypersensitivity reactions due to peanut allergy
20 December 2016 - Astellas and Immunomic Therapeutics today announced that the U.S. FDA has granted fast track designation for the drug candidate ASP0892 for the mitigation of severe hypersensitivity reactions due to peanut allergy.
ASP0892 is a new DNA vaccine program based on the investigational LAMP-Vax platform.
A Phase I clinical trial to evaluate the safety, tolerability and immune response of ASP0892 in adults allergic to peanuts has been initiated.
